Home › Companies › Arcus Biosciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2026: 6 items on Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2026: 6 passed (calculated).
Notable dissent: 4 directors (17.6%, 17.6%, 17.6%, 11.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dietmar Berger, M.D., Ph.D. | 85,949,508 | -- | -- | 18,338,022 | 13,573,227 | 82% | Passed (calculated) | — |
| Elect Director: David Lacey, M.D. | 85,974,583 | -- | -- | 18,312,947 | 13,573,227 | 82% | Passed (calculated) | — |
| Elect Director: Nicole Lambert | 92,653,341 | -- | -- | 11,634,189 | 13,573,227 | 89% | Passed (calculated) | — |
| Elect Director: Johanna Mercier | 85,941,754 | -- | -- | 18,345,776 | 13,573,227 | 82% | Passed (calculated) | — |
| 2. The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 | 112,905,582 | 4,767,430 | 187,745 | -- | -- | 96% | Passed (calculated) | — |
| 3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement | 94,920,421 | 9,337,368 | 29,741 | -- | 13,573,227 | 91% | Passed (calculated) | — |
Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
250 asset managers disclosed a vote on at least one Arcus Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: David Lacey, M.D.
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: David Lacey, M.D.”): 85,974,583 for, 18,312,947 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 27,294,920 for, 6,096,290 withheld, 132 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,445,214 | 0 | 132 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 8,245 | 0 | 0 | 3,649,002 | Withhold |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 768,350 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Aberdeen | 0 | 0 | 0 | 266,041 | Withhold |
| First Trust | 0 | 0 | 0 | 241,689 | Withhold |
| TIAA | 0 | 0 | 0 | 210,638 | Withhold |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 0 | 58,100 | Mixed |
| Jackson National | 0 | 0 | 0 | 149,532 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 129,106 | Withhold |
| Invesco | 0 | 0 | 0 | 100,687 | Withhold |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 66,723 | 0 | 0 | 11,406 | Mixed |
| Thrivent | 0 | 0 | 0 | 77,528 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 74,700 | Withhold |
| Bridge Builder Trust | 22,058 | 0 | 0 | 51,408 | Mixed |
| Principal | 0 | 0 | 0 | 72,189 | Withhold |
| ProShares | 0 | 0 | 0 | 66,038 | Withhold |
| Empower | 0 | 0 | 0 | 60,027 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 58,201 | Withhold |
| Northern Trust | 0 | 0 | 0 | 49,426 | Withhold |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Dietmar Berger, M.D., Ph.D.
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Dietmar Berger, M.D., Ph.D.”): 85,949,508 for, 18,338,022 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 30,355,930 for, 3,035,272 withheld, 140 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,410,256 | 0 | 140 | 34,950 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,646,532 | 0 | 0 | 10,715 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 768,350 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Aberdeen | 0 | 0 | 0 | 266,041 | Withhold |
| First Trust | 0 | 0 | 0 | 241,689 | Withhold |
| TIAA | 0 | 0 | 0 | 210,638 | Withhold |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 0 | 58,100 | Mixed |
| Jackson National | 130,963 | 0 | 0 | 18,569 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 129,106 | Withhold |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 0 | 0 | 0 | 84,214 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 78,129 | Withhold |
| Thrivent | 0 | 0 | 0 | 77,528 | Withhold |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 22,058 | 0 | 0 | 51,408 | Mixed |
| Principal | 0 | 0 | 0 | 72,189 | Withhold |
| ProShares | 0 | 0 | 0 | 66,038 | Withhold |
| Empower | 0 | 0 | 0 | 60,027 | Withhold |
| Lincoln Financial | 51,100 | 0 | 0 | 7,101 | Mixed |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Johanna Mercier
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Johanna Mercier”): 85,941,754 for, 18,345,776 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 30,355,930 for, 3,035,272 withheld, 140 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,410,256 | 0 | 140 | 34,950 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,646,532 | 0 | 0 | 10,715 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 768,350 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Aberdeen | 0 | 0 | 0 | 266,041 | Withhold |
| First Trust | 0 | 0 | 0 | 241,689 | Withhold |
| TIAA | 0 | 0 | 0 | 210,638 | Withhold |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 0 | 58,100 | Mixed |
| Jackson National | 130,963 | 0 | 0 | 18,569 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 129,106 | Withhold |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 0 | 0 | 0 | 84,214 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 78,129 | Withhold |
| Thrivent | 0 | 0 | 0 | 77,528 | Withhold |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 22,058 | 0 | 0 | 51,408 | Mixed |
| Principal | 0 | 0 | 0 | 72,189 | Withhold |
| ProShares | 0 | 0 | 0 | 66,038 | Withhold |
| Empower | 0 | 0 | 0 | 60,027 | Withhold |
| Lincoln Financial | 51,100 | 0 | 0 | 7,101 | Mixed |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Nicole Lambert
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Nicole Lambert”): 92,653,341 for, 11,634,189 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 31,316,916 for, 2,074,339 withheld, 87 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,445,259 | 0 | 87 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,652,652 | 0 | 0 | 4,595 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 768,350 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Aberdeen | 0 | 0 | 0 | 266,041 | Withhold |
| First Trust | 0 | 0 | 0 | 241,689 | Withhold |
| TIAA | 0 | 0 | 0 | 210,638 | Withhold |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 0 | 58,100 | Mixed |
| Jackson National | 0 | 0 | 0 | 149,532 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,106 | 0 | 0 | 0 | For |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 66,723 | 0 | 0 | 11,406 | Mixed |
| Thrivent | 0 | 0 | 0 | 77,528 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 74,700 | Withhold |
| Bridge Builder Trust | 22,058 | 0 | 0 | 51,408 | Mixed |
| Principal | 0 | 0 | 0 | 72,189 | Withhold |
| ProShares | 0 | 0 | 0 | 66,038 | Withhold |
| Empower | 0 | 0 | 0 | 60,027 | Withhold |
| Lincoln Financial | 51,100 | 0 | 0 | 7,101 | Mixed |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Prior year: 94.0% for (June 10, 2025 meeting) ▼ 2.9 pts
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.
Arcus Biosciences, Inc.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 94,920,421 for, 9,337,368 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,433,187 | 12,159 | 0 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,655,497 | 1,750 | 0 | 0 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 768,350 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 266,041 | 0 | 0 | Against |
| First Trust | 241,689 | 0 | 0 | 0 | For |
| TIAA | 210,638 | 0 | 0 | 0 | For |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 177,556 | 0 | 0 | 0 | For |
| Jackson National | 130,963 | 18,569 | 0 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,106 | 0 | 0 | 0 | For |
| Invesco | 0 | 100,687 | 0 | 0 | Against |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 78,129 | 0 | 0 | Against |
| Thrivent | 77,528 | 0 | 0 | 0 | For |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,466 | 0 | 0 | 0 | For |
| Principal | 72,189 | 0 | 0 | 0 | For |
| ProShares | 66,038 | 0 | 0 | 0 | For |
| Empower | 60,027 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,100 | 7,101 | 0 | 0 | Mixed |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Fund voting reports, all 73 managers: 32,763,247 for, 618,715 against, 11,080 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 31,424,760 | 0 | 0 | 0 | For |
| Wellington | 5,771,705 | 0 | 0 | 0 | For |
| State Street | 5,336,834 | 18,905 | 0 | 0 | For |
| BlackRock | 3,789,347 | 23,495 | 0 | 0 | For |
| MONTANOVA CAPITAL, LLC | 3,605,278 | 0 | 0 | 0 | For |
| Woodline Partners LP | 3,135,709 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,256,471 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 0 | 1,908,245 | 0 | 0 | Against |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,654,754 | 0 | 0 | Against |
| Siren, L.L.C. | 1,395,000 | 0 | 0 | 0 | For |
| Fidelity | 1,172,218 | 0 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 1,134,935 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 1,077,276 | 35,078 | 0 | 0 | For |
| Logos Global Management LP | 0 | 1,100,000 | 0 | 0 | Against |
| Charles Schwab | 898,762 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 790,613 | 0 | 0 | Against |
| Aberdeen | 0 | 766,376 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 727,349 | 0 | 0 | 0 | For |
| Vanguard | 707,036 | 0 | 0 | 0 | For |
| Northern Trust | 676,637 | 11,006 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 494,591 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 477,819 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 443,829 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 434,868 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 423,889 | 0 | 0 | 0 | For |
Institutional-manager reports, all 204 managers: 69,957,259 for, 7,762,931 against, 45 abstained, 128 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 98.0% for (June 10, 2025 meeting) ▼ 2.1 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Arcus Biosciences, Inc.’s own tally for this item (“2. The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending Decemb”): 112,905,582 for, 4,767,430 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 32,474,930 for, 905,332 against, 11,080 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,433,220 | 12,126 | 0 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,657,068 | 179 | 0 | 0 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 768,350 | 0 | 0 | Against |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Aberdeen | 266,041 | 0 | 0 | 0 | For |
| First Trust | 241,689 | 0 | 0 | 0 | For |
| TIAA | 210,638 | 0 | 0 | 0 | For |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 177,556 | 0 | 0 | 0 | For |
| Jackson National | 149,532 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,106 | 0 | 0 | 0 | For |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 78,129 | 0 | 0 | 0 | For |
| Thrivent | 77,528 | 0 | 0 | 0 | For |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,466 | 0 | 0 | 0 | For |
| Principal | 72,189 | 0 | 0 | 0 | For |
| ProShares | 66,038 | 0 | 0 | 0 | For |
| Empower | 60,027 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,201 | 0 | 0 | 0 | For |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,773,162 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.90% |
| 2 | BlackRock | 7.97% |
| 3 | State Street | 2.91% |
| 4 | Fidelity | 2.51% |
| 5 | Charles Schwab | 0.61% |
| 6 | Delaware/Macquarie | 0.30% |
| 7 | Aberdeen | 0.21% |
| 8 | First Trust | 0.19% |
| 9 | TIAA | 0.17% |
| 10 | Hartford | 0.15% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 24.99% |
| 2 | Wellington | 4.59% |
| 3 | State Street | 4.26% |
| 4 | BlackRock | 3.03% |
| 5 | MONTANOVA CAPITAL, LLC | 2.87% |
| 6 | Woodline Partners LP | 2.49% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.79% |
| 8 | SAMLYN CAPITAL, LLC | 1.52% |
| 9 | BNP Paribas Asset Management Holding S.A. | 1.32% |
| 10 | Siren, L.L.C. | 1.11% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | 24.99% | Schedule 13D, filed August 7, 2026 |
| BlackRock, Inc. | 12,736,927 | 10.13% | Schedule 13G, filed January 8, 2026 |
| Vanguard Group | 7,962,874 | 6.33% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 6,089,516 | 4.84% | Form 13F, quarter ended March 31, 2026 |
| State Street | 5,412,901 | 4.30% | Form 13F, quarter ended March 31, 2026 |
| Terry Rosen, Ph.D. | 2,592,608 | 2.06% | Proxy statement (DEF 14A), table as of March 1, 2026 |
| Geode Capital | 2,252,367 | 1.79% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 1,426,223 | 1.13% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 1,420,435 | 1.13% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 1,210,754 | 0.96% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 125,773,162 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Arcus Biosciences, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 250 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,990 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Arcus Biosciences (RCUS) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arcus-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.